Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.13%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.49 per share when it actually produced a loss of $0.40, delivering a surprise of 18.37%. Over the last four quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisd ...

Exhibit 99.1 Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights FDA advisory committee voted favorably that the data support arimoclomol as effective treatment for patients with NPC; PDUFA date of September 21, 2024 Pro-forma June 30, 2024, cash, cash equivalents, investments and net proceeds from underwritten public offering total $113.8 million following the closing on August 12, 2024 Conference call scheduled for today, August 13, 2024, at 4:30 p.m. ET Celebration, ...

CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company ("Zevra"), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expecte ...

CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at Canaccord Genuity's 44th Annual Growth Conference in Boston, MA, on Wednesday, August 14, 2024, at 10:30 a.m. ET. Members of the executive team will be available for one-on-one investor meetings with registered attendees throughout the conference. Live we ...

CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at Canaccord Genuity's 44th Annual Growth Conference in Boston, MA, on Wednesday, August 14, 2024, at 10:30 a.m. ET. Members of the executive team will be available for one-on-one investor meetings with registered attendees throughout the conference. Live ...

Zevra Therapeutics (ZVRA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August ...

CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C (NPC). "We are extremely pleased with the committee's recognition of the benefits of arimo ...

CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C (NPC). "We are extremely pleased with the committee's recognition of the benefits of arimo ...

CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Tuesday, August 13, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the second quarter of 2024. The link to the audio webcast will be accessible via the Investor Relations section of the Company's website, https://investors.zevra.com/. To join the meeting by ...